SABS

SAB BIO is a clinical-stage biopharmaceutical company developing fully human, multi-specific polyclonal immunoglobulin therapies using its proprietary Tc Bovine platform. The company is currently focused on autoimmune disease, with lead candidate SAB-142 being developed as a disease-modifying human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes. SAB BIO has repositioned its strategy around autoimmune disorders after earlier work in infectious disease and now appears centered on advancing SAB-142 through a registrational Phase 2b study. The company is publicly traded on Nasdaq and combines a differentiated antibody-generation platform with in-house expertise in transchromosomic cattle-derived hIgG therapeutics.